Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII | MicrobiomeTrials← Back to trialsNCT07326566
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-05-05Est. Completion: 2028-11
Enrollment target: 162 participants Locations- University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, Alabama, United States
- Highlands Oncology Group, Springdale, Arkansas, United States
- UCSD Moores Cancer Center, La Jolla, California, United States
- Cedars-Sinai Medical Center, Los Angeles, California, United States
- UC Irvine Health, Orange, California, United States
- Stanford University, Palo Alto, California, United States
- Yale Cancer Center, New Haven, Connecticut, United States
- Johns Hopkins Sibley Memorial Hospital, Washington D.C., District of Columbia, United States
- Miami Cancer Institute, Miami, Florida, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- Piedmont Oncology Research, Atlanta, Georgia, United States
- Johns Hopkins Sidney Kimmel Cancer Center - Baltimore, Baltimore, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
Other microbiome trials you might be interested in
Newly Diagnosed GlioblastomaMGMT-Unmethylated Glioblastoma
The Primary Objective of this study is to evaluate the efficacy and safety of teniposide in combination with temozolomid…
Multiple LocationsEst. completion Mar 2030
GlioblastomaGliosarcomaGBMGlioblastoma MultiformeGlioblastoma, IDH-wildtypeRecurrent Glioblastoma
Paclitaxel is among the most active agents against glioblastoma in preclinical models. However, its clinical use has bee…
University of Michigan, Ann Arbor, Michigan, United StatesHenry Ford Cancer- Detroit, Detroit, Michigan, United StatesWashington University School of Medicine Siteman Cancer Center, St Louis, Missouri, United StatesUniversity of Nebraska Medical Center, Omaha, Nebraska, United StatesJohn Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United StatesRutgers Cancer Institute, New Brunswick, New Jersey, United StatesAtlantic Health, Summit, New Jersey, United StatesNorthwell Health Center for Advanced Medicine - Brain Tumor Center, Lake Success, New York, United StatesColumbia University Irving Medical Center, New York, New York, United StatesMontefiore Medical Center, The Bronx, New York, United StatesCleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United StatesOhio State University, Columbus, Ohio, United StatesThomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center, Philadelphia, Pennsylvania, United StatesUPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United StatesPrisma Health, Greenville, South Carolina, United StatesUT MD Anderson Cancer Center, Houston, Texas, United StatesHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United StatesInova Schar Cancer Institute, Fairfax, Virginia, United StatesVCU Massey Comprehensive Cancer Center, Richmond, Virginia, United StatesUniversity of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United StatesChicago, United StatesEst. completion Dec 31, 2027
Glioblastoma, IDH-Wildtype
This phase II trial compares the effect of adding WSD0922-FU to temozolomide versus temozolomide alone in slowing diseas…
Scottsdale, United StatesEst. completion Aug 31, 2036